Brexucabtagene Autoleucel

Definition

A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of abrexucabtagene autoleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development. KTE-X19 has the same construct as axicabtagene ciloleucel, but differs in the manufacturing process in that KTE-X19 includes specific T-cell selection and lymphocyte enrichment necessary for activity against certain B-cell malignancies.

Also known as Anti-CD19 Autologous CAR-CD28 T-cells KTE-X19, Brexu-cel, BREXUCABTAGENE AUTOLEUCEL, KTE X19, KTE-X19, KTEX19, Tecartus — per NCIT

Also identified as

• ATC L01XL06 per RXNORM
• NCIT NCIT:C170439 per NCIT
• SCTID 895363000 per RXNORM
• SCTID 895369001 per RXNORM
• UNII 4MD2J2T8SJ per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.